April 08, 2015
Just weeks before their retrial, Abbott Laboratories urged a California federal judge Wednesday to throw out GlaxoSmithKline's case claiming Abbott violated a license to use one of its HIV drugs, arguing that because GlaxoSmithKline's antitrust claims have been dropped, the case no longer has ties to California.
March 27, 2015
GlaxoSmithKline has urged a California federal judge to rule that the court has jurisdiction over its suit against Abbott Laboratories, saying that although it dropped its federal antitrust claims over the raised price of an HIV drug it licensed, there is plenty to connect Abbott to the state.
January 07, 2015
A California federal judge on Wednesday refused to let GlaxoSmithKline substitute new expert witnesses in an impending retrial over allegations that Abbott Laboratories violated antitrust laws when it raised prices on an HIV drug it licensed to GlaxoSmithKline, saying she didn't think the substitutions were necessary.
November 13, 2014
Abbott Laboratories urged a California federal judge on Thursday to rule it didn't violate antitrust or deceptive trade laws when it raised prices on an HIV drug it had licensed to GlaxoSmithKline, saying a retrial ordered by the Ninth Circuit should be limited to GSK's contract claims.
September 06, 2011
A California federal judge on Tuesday shot down Abbott Laboratories' bid to duck a $3.5 million jury verdict in GlaxoSmithKline PLC's contract and antitrust suit over a licensing deal for Abbott's HIV drug Norvir, finding that the evidence at trial backed up the jury's findings.
August 08, 2011
Abbott Laboratories sought Friday to overturn a $3.5 million jury verdict in a dispute with GlaxoSmithKline PLC over a licensing deal for Norvir, having already fought off GSK's antitrust challenge over its decision to drastically raise prices for the HIV drug.
March 30, 2011
Abbott Laboratories must pay GlaxoSmithKline PLC $3.5 million for raising the price of HIV drug Norvir despite a deal that let GSK include it in a drug cocktail, but Abbott did not break antitrust law, a California jury said Wednesday.